Cargando…

Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV

Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV can reinfect the population engaging in high-risk behavior. An increasing incidence of acute hepatitis C infection in people living with HIV (PLWH) has been described in recent years. This retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Chien-Yu, Ku, Shin-Yen, Lin, Yi-Chun, Chen, Cheng-Pin, Cheng, Shu-Hsing, Lin, I-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874599/
https://www.ncbi.nlm.nih.gov/pubmed/35216032
http://dx.doi.org/10.3390/v14020439
_version_ 1784657727155339264
author Cheng, Chien-Yu
Ku, Shin-Yen
Lin, Yi-Chun
Chen, Cheng-Pin
Cheng, Shu-Hsing
Lin, I-Feng
author_facet Cheng, Chien-Yu
Ku, Shin-Yen
Lin, Yi-Chun
Chen, Cheng-Pin
Cheng, Shu-Hsing
Lin, I-Feng
author_sort Cheng, Chien-Yu
collection PubMed
description Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV can reinfect the population engaging in high-risk behavior. An increasing incidence of acute hepatitis C infection in people living with HIV (PLWH) has been described in recent years. This retrospective cohort study was conducted in PLWH who completed HCV therapy between June 2009 and June 2020 at an HIV care hospital, to analyze their basic characteristics and risky behavior. Of 2419 patients, 639 were diagnosed with HCV infection and 516 completed the HCV therapy with a sustained virologic response. In total, 59 patients (11.4%) were reinfected with acute hepatitis C, and the median time to reinfection was 85.3 weeks (IQR: 57–150). The incidence of reinfection was 6.7 cases/100 person-years. The factors associated with reinfection were being male (AHR, 8.02; 95% CI 1.08–59.49), DAA (direct-acting antiviral) treatment (AHR, 2.23; 95% CI 1.04–4.79), liver cirrhosis (AHR, 3.94; 95% CI 1.09–14.22), heroin dependency (AHR: 7.41; 95% CI 3.37–14.3), and HIV viral loads <50 copies/mL at the follow-up (AHR: 0.47, 95% CI 0.24–0.93) in the subgroup of people who inject drugs (PWID). Amphetamine abuse (AHR: 20.17; 95% CI 2.36–172.52) was the dominant factor in the subgroup of men who have sex with men (MSM). Our study suggests that education and behavioral interventions are needed in this population to prevent reinfection.
format Online
Article
Text
id pubmed-8874599
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88745992022-02-26 Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV Cheng, Chien-Yu Ku, Shin-Yen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Lin, I-Feng Viruses Article Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV can reinfect the population engaging in high-risk behavior. An increasing incidence of acute hepatitis C infection in people living with HIV (PLWH) has been described in recent years. This retrospective cohort study was conducted in PLWH who completed HCV therapy between June 2009 and June 2020 at an HIV care hospital, to analyze their basic characteristics and risky behavior. Of 2419 patients, 639 were diagnosed with HCV infection and 516 completed the HCV therapy with a sustained virologic response. In total, 59 patients (11.4%) were reinfected with acute hepatitis C, and the median time to reinfection was 85.3 weeks (IQR: 57–150). The incidence of reinfection was 6.7 cases/100 person-years. The factors associated with reinfection were being male (AHR, 8.02; 95% CI 1.08–59.49), DAA (direct-acting antiviral) treatment (AHR, 2.23; 95% CI 1.04–4.79), liver cirrhosis (AHR, 3.94; 95% CI 1.09–14.22), heroin dependency (AHR: 7.41; 95% CI 3.37–14.3), and HIV viral loads <50 copies/mL at the follow-up (AHR: 0.47, 95% CI 0.24–0.93) in the subgroup of people who inject drugs (PWID). Amphetamine abuse (AHR: 20.17; 95% CI 2.36–172.52) was the dominant factor in the subgroup of men who have sex with men (MSM). Our study suggests that education and behavioral interventions are needed in this population to prevent reinfection. MDPI 2022-02-21 /pmc/articles/PMC8874599/ /pubmed/35216032 http://dx.doi.org/10.3390/v14020439 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cheng, Chien-Yu
Ku, Shin-Yen
Lin, Yi-Chun
Chen, Cheng-Pin
Cheng, Shu-Hsing
Lin, I-Feng
Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV
title Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV
title_full Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV
title_fullStr Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV
title_full_unstemmed Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV
title_short Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV
title_sort incidence and risk factors of reinfection with hcv after treatment in people living with hiv
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874599/
https://www.ncbi.nlm.nih.gov/pubmed/35216032
http://dx.doi.org/10.3390/v14020439
work_keys_str_mv AT chengchienyu incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv
AT kushinyen incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv
AT linyichun incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv
AT chenchengpin incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv
AT chengshuhsing incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv
AT linifeng incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv